This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Study sponsor: AnaptysBio, Inc. · ANAB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-16Actual
Enrollment · participants201Actual
Source updated2025-02-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.